In this study, researchers sought to determine the impact of the FDA’s Accelerated Approval pathway among patients with solid tumors.

Overall survival data showed a 50% reduction in the risk of death with the regimen compared with surgery alone.

High rates of vulnerability on a geriatric assessment were identified in a cohort of fit patients aged 60 years or older with acute myeloid leukemia.

(HealthDay News) — For women with a history of breast cancer, real (RA) and sham acupuncture (SA) produce clinically meaningful improvements in perceived cognitive impairment, according to a study ...

The current study assesses whether the MNW could address global disparities in oncology education by reaching low- and middle-income countries and if it was able to advance gender inclusivity in ...

Following the expanded approval, the accelerated approval for the later-line CLL/SLL was converted to a traditional approval.

Some pediatric patients with low-risk acute myeloid leukemia can receive 4 cycles of chemotherapy, rather than 5, without affecting outcomes.

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

In premenopausal women with early breast cancer, survival is not affected by fertility preservation procedures, researchers report.

Investigators evaluated atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for patients with recurrent ovarian cancer.

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

The American Society of Hematology/ASH 2025 meeting included AML results from AAML1831, MyeChild01, BIG-1, and PALG-AML1/2016 studies.